logo
Bad diets, too many meds, no exercise: A look inside the latest ‘Make America Healthy Again' report

Bad diets, too many meds, no exercise: A look inside the latest ‘Make America Healthy Again' report

CTV Newsa day ago
Savannah Knott hangs up her backpack for the day on the first day in her second grade classroom at Mary Carrico Catholic School, Tuesday, Aug. 12, 2025, in Knottsville, Ky. (Greg Eans/The Messenger-Inquirer via AP)
WASHINGTON — A report that U.S. Health and Human Services Secretary Robert F. Kennedy Jr. has promised will improve the health of America's children does not call on the government to make significant changes to its food or farming policies, according to a draft document obtained by The Associated Press.
The 'Make America Healthy Again' strategy report is supposed to be one of Kennedy's signature achievements as the nation's health secretary, giving the government a roadmap to help its citizens lose weight, reduce chronic diseases and exercise more. Before coming to Washington, Kennedy had spent much of his career decrying the harms of chemicals sprayed on crops, prescription drugs, ultraprocessed foods, and vaccines.
His coalition, then, has expected him to take bold action as the nation's top health leader. But a draft of the so-called 'MAHA' report, first reported by The New York Times Thursday night, mostly calls on the government to further study chronic diseases, bad air quality, Americans' diets and prescription drug use.
The report lays out four problem areas – poor diet, chemical exposure, lack of physical activity and overuse of medications -- that are to blame for chronic diseases in the U.S.
The White House has held off on publicly releasing the report, which was submitted to U.S. President Donald Trump on Tuesday. The latest report is the policy companion to a 'MAHA' report released in May, which was found to have several errors in it.
White House spokesman Kush Desai refused to confirm whether the copy obtained by the Associated Press was a final version, though HHS officials have insisted the report has been finalized since Tuesday.
'President Trump pledged to Make America Healthy Again, and the Administration is committed to delivering on that pledge with Gold Standard Science,' Desai said. 'Until officially released by the White House and MAHA Commission, however, any documents purporting to be the second MAHA Report should be considered as nothing more than speculative literature.'
Some in the agricultural industry had warily anticipated the report, fearing it would call for bans or investigations into the use of pesticides and herbicides that farmers in the U.S. regularly spray on crops to control weeds and enhance yields. Other farmers were concerned about how the report may target the use of corn syrup, a common sweetener, in American foods. Both products have been a central talking point in Kennedy's 'MAHA' movement, which has attracted a diverse coalition of suburban and rural moms, Trump supporters and liberals concerned about the nation's food supply.
Instead, the report calls for an 'awareness' campaign to raise confidence in pesticides.
Concerns from the agricultural industry waned as the report hit the president's desk, with one of Kennedy's closest advisers, Calley Means, calling for MAHA supporters to work with major farm companies on Tuesday.
Means also acknowledged that the 'pace of political change' can be frustrating.
'We need to build bridges,' Means said, adding that: 'We are not going to win if the soybean farmers and the corn growers are our enemy.'
Means did not respond to a request for comment on Friday. A spokesman for Kennedy also declined to comment.
The report urges the National Institutes of Health – which is facing a 40 per cent cut to its budget under the Trump administration – to undertake several studies on Americans' health, including research on vaccine injury, autism, air quality, water quality, prescription drugs, and nutrition.
The report also calls for changes to the foods served in schools and hospitals, something that will be hard to deliver with the Trump administration's funding cuts, said Kari Hamerschlag, the deputy director of the food and agriculture at the nonprofit Friends of the Earth. Earlier this year, the Republican-led administration wiped out US$1 billion set aside that helped food banks and schools procure food directly from local farmers.
'This is not going to transform our food and farming system,' Hamerschlag said. 'This is not going to make people healthier. They need to put resources behind their recommendations.'
___
Amanda Seitz, The Associated Press
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Gazan woman evacuated to Italy in a ‘state of severe physical deterioration' dies in hospital
Gazan woman evacuated to Italy in a ‘state of severe physical deterioration' dies in hospital

Toronto Star

time13 minutes ago

  • Toronto Star

Gazan woman evacuated to Italy in a ‘state of severe physical deterioration' dies in hospital

MADRID (AP) — A 20-year old Palestinian woman described as being in a 'state of severe physical deterioration' has died after being transferred to Italy for treatment, the hospital said Saturday. The patient was admitted to Pisa University Hospital late Wednesday and died on Friday. She was removed from the Gaza Strip as part of a humanitarian mission and arrived with a 'with a very complex, compromised clinical picture,' according to the hospital.

Gazan woman evacuated to Italy in a ‘state of severe physical deterioration' dies in hospital
Gazan woman evacuated to Italy in a ‘state of severe physical deterioration' dies in hospital

Winnipeg Free Press

time13 minutes ago

  • Winnipeg Free Press

Gazan woman evacuated to Italy in a ‘state of severe physical deterioration' dies in hospital

MADRID (AP) — A 20-year old Palestinian woman described as being in a 'state of severe physical deterioration' has died after being transferred to Italy for treatment, the hospital said Saturday. The patient was admitted to Pisa University Hospital late Wednesday and died on Friday. She was removed from the Gaza Strip as part of a humanitarian mission and arrived with a 'with a very complex, compromised clinical picture,' according to the hospital. She died after entering a respiratory crisis and subsequently going into cardiac arrest, it said in a statement. Hospital staff had performed tests and started supportive therapy before she died, the statement said. The woman, named by Italian media as Marah Abu Zuhri, had arrived in Italy with her mother. Italian Foreign Minister Antonio Tajani said almost 120 Gazans — 31 patients and their families — had been flown to Rome, Milan and Pisa on three planes. In a post on X, Tajani said that it was the 14th medical evacuation of Palestinians that Italy had conducted since January 2024, and the largest. The hospital did not specify whether the woman had suffered from malnutrition, but said that she had arrived in a 'state of severe physical deterioration.' Eugenio Giani, leader of the Tuscan region, expressed his condolences Saturday for the woman's death. Earlier in the week, United Nations spokesman Stephane Dujarric said that starvation and malnutrition in Gaza were at their highest levels since the Israel-Hamas war began. Wednesdays What's next in arts, life and pop culture. The U.N. says nearly 12,000 children under 5 were found to have acute malnutrition in July — including more than 2,500 with severe malnutrition, the most dangerous level. The World Health Organization says the numbers are likely an undercount. Israeli Prime Minister Benjamin Netanyahu said last month no one in Gaza is starving. 'There is no policy of starvation in Gaza, and there is no starvation in Gaza,' he said. U.S. President Donald Trump responded to Netanyahu's claim by noting the images emerging of emaciated people. 'I don't know,' Trump said when asked if he agreed with the Israeli leader's comment. 'I mean, based on television, I would say not particularly because those children look very hungry.' Over the past two weeks, Israel has allowed around triple the amount of food into Gaza than what had been entering since late May. That was after 2.5 months when Israel barred all food, medicine and other supplies, saying it was to pressure Hamas to release hostages taken during its October 2023 attack that launched the war.

2 Top Dividend Stocks to Buy on the Dip
2 Top Dividend Stocks to Buy on the Dip

Globe and Mail

time2 hours ago

  • Globe and Mail

2 Top Dividend Stocks to Buy on the Dip

Key Points Pfizer's pipeline in oncology, combined with its cost-cutting initiatives, could help it bounce back. Merck could move beyond Keytruda thanks to newer approvals and a novel formulation of the medicine. Both companies have increased their dividends at a decent rate over the past five years. 10 stocks we like better than Pfizer › Dividend stocks are a great investment choice for many reasons. Buying on the dip is even better, provided, of course, they have the means to bounce back. Investors looking for companies that fit this profile should strongly consider Pfizer (NYSE: PFE) and Merck (NYSE: MRK). These two market leaders have lagged broader equities over the trailing-12-month period, but for those focused on the long game, they still look attractive. Here's the rundown. 1. Pfizer Over the past few years, Pfizer has dealt with worsening financial results and stiff competition for some products. It also faces the prospect of losing patent protection for others; these include Eliquis, an anticoagulant that is one of its top-selling drugs, and Xtandi, a cancer treatment. Both will lose their patents in the U.S. within the next few years. These challenges have led to terrible stock-market performance. However, the sell-off may have gone too far. At current levels, Pfizer's shares look attractive. One reason the company should bounce back and continue to deliver strong returns over the long run is its deep pipeline, particularly in oncology, one of the largest therapeutic areas in the industry. Pfizer currently has five blockbuster cancer medicines, and plans to raise that number to eight by 2030. Pfizer has exciting candidates in other areas as well, and in recent years has earned approval for several new products. Though these aren't yet meaningfully contributing to its top-line growth, they should do so eventually as they earn label expansion. The company's vaccine for respiratory syncytial virus (RSV), Abrysvo, generated $143 million in sales in the second quarter, which isn't bad for a product approved in 2023. It also recently earned a label expansion in Europe for adults age 18 to 59 (it was previously indicated for those 60 and older). Pfizer should make progress with Abrysvo and other newer launches. The company has also been reducing expenses. These initiatives were likely partly responsible for Pfizer's earnings beat during the second quarter. Management intends to achieve $4.5 billion in net cost savings this year and pursue further reductions in the years ahead, efforts that should help improve profitability. Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in the past five years. While the stock may take some time to recover, Pfizer could be an excellent long-term investment for income-seeking investors. 2. Merck Merck is facing several issues, none more important than increased competition for its best-selling drug, cancer medicine Keytruda, and an upcoming patent cliff in 2028 for the medicine. Also, the company's second-quarter results were not strong: Revenue declined by 2% year over year to $15.8 billion, while adjusted earnings per share declined by 7% to $2.13. However, there were some bright spots for the company. Most notably, Winrevair -- one of its newest launches, which earned approval last year -- reported sales of $336 million. Winrevair is a therapy for pulmonary arterial hypertension with a new mechanism of action. It should become a blockbuster relatively soon. Merck's business in animal health -- where it's one of the leaders -- also performed well, with sales from that segment rising by 11% year over year to $1.6 billion in the second quarter. Meanwhile, Merck has some exciting pipeline candidates that should help it overcome Keytruda-related challenges. One of them is a subcutaneous version of Keytruda, which has already aced phase 3 studies and will help extend the medicine's patent protection. Merck has also significantly improved its pipeline in recent years thanks to licensing agreements. Its candidates include promising cancer products and weight loss medicines. Just as Winrevair appears to be a major success, Merck is also likely to develop innovative therapies that will mitigate potential Keytruda-related revenue losses. So, despite recent setbacks, the business could bounce back given Merck's history of innovation. Turning to Merck's dividend program, the company now offers a forward yield of 4.1%, with its dividends increasing by 39% over the past five years. The stock remains a good pick for dividend seekers. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store